Lung Cancer - Other

JANS Article

FDA Approves Drug Which Makes Lung Cancer Glow

January 6, 2023 | Cameron LindSilver Contributor

The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light. Surgical removal of lung tumors...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

April 19, 2023 | Mark FergusonBronze Contributor

This study used lung cancer screening trial low dose CT scans to develop a model (Sybil) that predicts the likelihood of development of a lung cancer within the next year....

JANS Article

Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery Guidelines for the Prevention of Cancer-Associated Venous Thromboembolism in Thoracic Surgery

March 23, 2023 | Cameron LindSilver Contributor

Thoracic oncology patients are a high-risk group for venous thromboembolism (VTE). The ESTS and AATS panel reviewed the evidence using the GRADE approach and made twenty-four recommendations for VTE prophylaxis,...

JANS Article

FDA Approves Drug Which Makes Lung Cancer Glow

January 6, 2023 | Cameron LindSilver Contributor

The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light....

JANS Article

The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non–Small Cell Lung Cancer

October 24, 2017 | Mark FergusonBronze Contributor

Surgical treatment of metastatic disease, particularly lung cancer metastases, is often controversial. This article reviews the literature on therapeutic surgical interventions, and comments on diagnostic, palliative, and consolidation roles for...

JANS Article

Lung Cancer Awareness Month—A Lot of Progress, But More Work Needs to Be Done

October 24, 2017 | Mark FergusonBronze Contributor

A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.

...
JANS Article

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

October 2, 2017 | Mark FergusonBronze Contributor

Researchers used a nanomaterial sensor array and pattern recognition statistical techniques to evaluate exhaled breath samples from patients with suspicious lesions on imaging. A total of 119 patients were included,...

JANS Article

Concordance Between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens

October 2, 2017 | Mark FergusonBronze Contributor

The authors demonstrated substantial concordance between sequencing of 39 genes in a liquid assay and routine diagnostic testing in tissue in 82 patients. Agreement was 98%, and the primary reason...

JANS Article

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer

August 2, 2017 | Mark FergusonBronze Contributor

This retrospective study of the association of BMI to long-term survival after resection of NSCLC identified BMI > 30kg/m2 as an independent predictor of survival. In a propensity score matched...

JANS Article

Scientific Advances in Thoracic Oncology 2016

August 2, 2017 | Mark FergusonBronze Contributor

This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by...

JANS Article

Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers

February 24, 2016 | Marcelo Jimenez

Routine use of PET scans to follow up asymptomatic patients do not affect survival, according to this retrospective analysis of a cohort of 97,152 lung cancer and 4,446 esophageal cancer...

JANS Article

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival

August 11, 2015 | Mark FergusonBronze Contributor

This single institution retrospective study evaluated the relationship of adenocarcinoma subtype to long-term survival after resection of stage I lung cancer. Patients with solid-predominant tumors experienced recurrences earlier, more often...

LOAD MORE
ADVERTISE ON CTSNET